Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Acquired by Xponance Inc.

Xponance Inc. grew its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 8.7% during the 4th quarter, HoldingsChannel.com reports. The firm owned 22,456 shares of the biopharmaceutical company’s stock after buying an additional 1,806 shares during the period. Xponance Inc.’s holdings in Alnylam Pharmaceuticals were worth $5,284,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Huntington National Bank lifted its stake in shares of Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 45 shares during the last quarter. Larson Financial Group LLC lifted its stake in shares of Alnylam Pharmaceuticals by 187.2% in the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 73 shares during the last quarter. R Squared Ltd acquired a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $33,000. True Wealth Design LLC lifted its stake in Alnylam Pharmaceuticals by 15,300.0% during the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 153 shares in the last quarter. Finally, OFI Invest Asset Management acquired a new position in Alnylam Pharmaceuticals during the 4th quarter worth about $35,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Trading Up 3.7 %

NASDAQ:ALNY opened at $253.44 on Thursday. The stock’s 50 day moving average price is $255.99 and its 200 day moving average price is $259.55. The company has a market capitalization of $32.81 billion, a PE ratio of -116.79 and a beta of 0.39. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). On average, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on ALNY. Needham & Company LLC reissued a “buy” rating and set a $320.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. Royal Bank of Canada reissued an “outperform” rating and set a $310.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. Scotiabank decreased their target price on Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating on the stock in a research note on Friday, February 14th. StockNews.com raised Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, March 13th. Finally, William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and twenty have issued a buy rating to the stock. Based on data from MarketBeat, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $304.26.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CFO Jeffrey V. Poulton sold 967 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $246,749.39. Following the transaction, the chief financial officer now directly owns 32,786 shares in the company, valued at approximately $8,366,003.62. This trade represents a 2.86 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total value of $362,246.40. Following the completion of the transaction, the executive vice president now owns 12,881 shares in the company, valued at $3,240,344.36. This trade represents a 10.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 71,234 shares of company stock worth $19,958,097. 1.50% of the stock is currently owned by insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.